.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Accenture
McKesson
Federal Trade Commission
AstraZeneca
Teva
Dow
Citi
Express Scripts
Merck

Generated: November 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022196

« Back to Dashboard
NDA 022196 describes ZOLPIMIST, which is a drug marketed by Magna Pharms and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug. Additional details are available on the ZOLPIMIST profile page.

The generic ingredient in ZOLPIMIST is zolpidem tartrate. There are thirty-one drug master file entries for this compound. Sixty-six suppliers are listed for this compound. Additional details are available on the zolpidem tartrate profile page.

Summary for 022196

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:2
Therapeutic Class:Sedatives/Hypnotics
Formulation / Manufacturing:see details

Pharmacology for NDA: 022196

Ingredient-typePyridines
Mechanism of ActionGABA A Agonists
Physiological EffectCentral Nervous System Depression

Suppliers and Packaging for NDA: 022196

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZOLPIMIST
zolpidem tartrate
SPRAY, METERED;ORAL 022196 NDA ECR Pharmaceuticals 0095-0950 0095-0950-05 1 CONTAINER in 1 CARTON (0095-0950-05) > 60 SPRAY, METERED in 1 CONTAINER
ZOLPIMIST
zolpidem tartrate
SPRAY, METERED;ORAL 022196 NDA ECR Pharmaceuticals 0095-0950 0095-0950-09 1 CONTAINER in 1 CARTON (0095-0950-09) > 8 SPRAY, METERED in 1 CONTAINER

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;ORALStrength5MG/SPRAY
Approval Date:Dec 19, 2008TE:RLD:Yes
Patent:► SubscribePatent Expiration:Oct 1, 2017Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF TRANSIENT INSOMNIA
Patent:► SubscribePatent Expiration:Aug 7, 2032Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF TRANSIENT INSOMNIA

Expired Orange Book Patents for NDA: 022196

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Magna Pharms
ZOLPIMIST
zolpidem tartrate
SPRAY, METERED;ORAL022196-001Dec 19, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Chinese Patent Office
Accenture
Medtronic
Cerilliant
Moodys
Cipla
Queensland Health
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot